Literature DB >> 17606980

PD-1 and PD-1 ligands: from discovery to clinical application.

Taku Okazaki1, Tasuku Honjo.   

Abstract

Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606980     DOI: 10.1093/intimm/dxm057

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  449 in total

1.  Antigen-induced regulation of T-cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors.

Authors:  Sten-Erik Bergström; Mehmet Uzunel; Toomas Talme; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

3.  PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells.

Authors:  Yan Ke; Deming Sun; Guomin Jiang; Henry J Kaplan; Hui Shao
Journal:  J Leukoc Biol       Date:  2010-08-25       Impact factor: 4.962

4.  PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.

Authors:  Victor Peña-Cruz; Sean M McDonough; Felipe Diaz-Griffero; Christopher P Crum; Ruben D Carrasco; Gordon J Freeman
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

Review 5.  Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?

Authors:  Zili Zhang; James T Rosenbaum; Wenwei Zhong; Carmen Lim; David J Hinrichs
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 6.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

7.  PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Authors:  Vrajesh V Parekh; Saif Lalani; Sungjune Kim; Ramesh Halder; Miyuki Azuma; Hideo Yagita; Vipin Kumar; Lan Wu; Luc Van Kaer
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

9.  Late-emerging strains of HIV induce T-cell homeostasis failure by promoting bystander cell death and immune exhaustion in naïve CD4 and all CD8 T-cells.

Authors:  Catherine N Kibirige; Frederick A Menendez; Hao Zhang; Tricia L Nilles; Susan Langan; Joseph B Margolick
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

10.  Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response.

Authors:  Yuxiang Rui; Tasuku Honjo; Shunsuke Chikuma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.